Corticosteroid-Loaded Liposomes for Topical Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for noninfectious anterior uveitis, such as steroid eye drops, suffer from poor ocular penetration, frequent administration requirements, and untargeted delivery, leading to inadequate inflammation control and steroid-related side effects like cataract and glaucoma.
Innovation Solution
Development of corticosteroid-loaded liposomes composed of non-charged vesicle-forming phospholipids with long-chain saturated fatty acids, administered subconjunctivally to directly target inflammatory cells, providing sustained intracellular release of corticosteroids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroid eye drops are administered frequently to achieve desired anti-inflammatory effect, then inflammation control is improved, but patient compliance deteriorates and treatment burden increases
Solution Approach 1:
The liposomal formulation transforms the static, rapid-release characteristics of conventional steroid eye drops into a dynamic, sustained-release system. The liposomes gradually release corticosteroids over time, maintaining therapeutic levels without requiring frequent administration, thus improving patient compliance while maintaining inflammation control
Solution Approach 2:
The invention changes the release rate parameter of the corticosteroid by encapsulating it in liposomes. This transforms the rapid washout characteristic of free steroid eye drops into a slow, controlled release profile, extending the duration of action and reducing administration frequency from hourly to less frequent intervals
2Reliability
If intensive steroid eye drop instillation is used to overcome poor ocular penetration, then therapeutic effect is improved, but drug loss to tear drainage increases
Solution Approach 1:
The liposomal formulation provides continuous drug delivery to the ocular surface and inflammatory cells. Instead of repeated bolus doses that are rapidly washed away, the liposomes continuously release corticosteroids at the target site, maintaining therapeutic action without requiring intensive instillation and minimizing drug loss to tear drainage
Solution Approach 2:
The liposomes act as an intermediary carrier that protects the corticosteroid from rapid washout by tear drainage. The liposomal encapsulation allows the drug to bypass the limitation of tear flow, delivering the active ingredient directly to inflammatory cells while minimizing loss to drainage
3Area of stationary object
If untargeted steroid delivery is used to treat inflamed areas, then broad coverage is achieved, but steroid-related side effects increase
Solution Approach 1:
The liposomal formulation enables localized drug delivery specifically to inflammatory cells and affected tissues. The liposomes target and adhere to inflamed areas, releasing corticosteroids locally at the site of inflammation while minimizing exposure of healthy ocular tissues to the drug, thus reducing the risk of steroid-related side effects like cataract and glaucoma
Solution Approach 2:
The liposomes serve as a targeted delivery vehicle that mediates between the corticosteroid and the inflammatory cells. This intermediary approach ensures the drug reaches the intended target (inflammatory cells) with high specificity, avoiding untargeted exposure of healthy tissues and thereby reducing harmful side effects
4Reliability
If conventional steroid eye drops are administered hourly to achieve adequate drug levels, then anti-inflammatory efficacy is improved, but treatment duration and time commitment increase
Solution Approach 1:
The liposomal formulation introduces a dynamic, time-extending mechanism to drug delivery. The sustained-release特性 of liposomes extends the duration of therapeutic action from hours to days or weeks, transforming the treatment regimen from intensive hourly administration to much less frequent dosing while maintaining adequate drug levels and anti-inflammatory efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves effective suppression of inflammation with reduced treatment frequency and lower side effects, as demonstrated by improved therapeutic outcomes and reduced incidence of steroid-related complications like cataract and glaucoma.
Implementation Method 1
Liposomes composed of non-charged vesicle-forming phospholipids, wherein said phospholipids comprise long-chain saturated fatty acids... comprising a corticosteroid in water-soluble form... providing sustained intracellular release of corticosteroids
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The invention relates to topical injection in inflamed lesions or areas with liposomal corticosteroids.